A population-based cohort (1996–2021) of 2.94 million individuals assigned female at birth found endometriosis conferred ...
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, ...
Prior authorization, fail-first step therapy, and market consolidation among pharmacy benefit managers (PBMs) are driving up ...
Real-world COPD data from ERS 2026 support RSV vaccination, but Jorgen Vestbo, MD, says cost remains the biggest barrier to ...
Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven ...
Delaying dupilumab initiation beyond 90 days after a severe asthma exacerbation was linked to a 32% increase in predicted ...
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on ...
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on ...
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per ...
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival ...
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on ...
HFpEF/HFmrEF represent roughly 60% to 75% of US heart failure, and registries report >70% HFpEF, yet morbidity and mortality appear similar across ejection fraction categories.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results